Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To BenefitBenzinga • 12/15/25
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/05/25
Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent ProgressBusiness Wire • 11/05/25
Viridian Therapeutics, Inc. (VRDN) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks Investment Research • 11/04/25
Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye DiseaseBusiness Wire • 11/03/25
Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common StockBusiness Wire • 10/22/25
Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 MillionBusiness Wire • 10/20/25
Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio UpdatesBusiness Wire • 09/15/25
These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 ResultsBenzinga • 08/07/25
Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/06/25
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial ResultsBusiness Wire • 08/06/25
Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone PaymentsBusiness Wire • 07/30/25
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business Wire • 07/03/25
Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)Business Wire • 05/20/25
Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)Business Wire • 05/07/25
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/06/25
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial ResultsBusiness Wire • 05/06/25
Viridian Therapeutics: Positive Data In TED, Strong Cash Position, 1.5-Year WindowSeeking Alpha • 03/02/25